Oops, He Did It Again – Another Charge Against Shkreli
Executive Summary
Prosecutors unsealed an additional charge of conspiracy to commit securities fraud against Martin Shkreli – infamously known for hiking up the price of a toxoplasmosis medicine by 5,000% – bringing the total number of criminal counts against the former drug company CEO to eight.
You may also be interested in...
Finance Watch: Two New VC Funds Raise $500m; One New US IPO; And Galena's 'Strategic Review'
Pivotal and Biomatics launch new VC funds totaling $300m and $200m, respectively; Spero raises a $51.7m Series C round; BeyondSpring is March's only US IPO, so far; Aurinia and TG Therapeutics capitalize on positive data with secondary offerings; and Galena hires a "strategic review" advisor.
It Was Shkreli's Show, But Pharma Was On Trial
The House Oversight and Government Reform Committee hearing on drug prices was the hottest spot in a very damp and cold Washington on Feb. 4 and former Turing Pharmaceutical Inc. CEO Martin Shkreli gave lawmakers and the overflow-crowd in attendance what they were anticipating: Several big smirky smiles, a lot of eye rolling and a refusal to testify – citing his "Act of Production Privilege" under the Fifth Amendment to the US Constitution at the advice of his counsel.
Shkreli's Ponzi Scheme Trifecta: Lies, Deceit And Greed
With the answer to the big question about Martin Shkreli out of the way – The FBI confirmed it didn't seize his $2m one-of-its-kind album of the American hip-hop group Wu-Tang Clan – what investors and patients likely are wondering is where do his companies, Turing Pharmaceuticals AG and KaloBios Pharmaceuticals Inc., go from here?